Citius Oncology (NASDAQ:CTOR) Trading Down 2.8% – Here’s What Happened

Citius Oncology, Inc. (NASDAQ:CTOR) fell 2.8% during trading on Monday . The stock traded as low as $0.62 and last traded at $0.6253. 114,215 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 431,019 shares. The stock had previously closed at $0.6431.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Oncology in a research report on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Citius Oncology presently has an average rating of “Hold” and an average target price of $6.00.

Citius Oncology Trading Down 2.8%

The company has a market cap of $55.20 million, a PE ratio of -2.02 and a beta of 3.02. The company has a current ratio of 0.83, a quick ratio of 0.32 and a debt-to-equity ratio of 0.07. The stock has a 50 day moving average price of $1.05 and a 200 day moving average price of $1.33.

Citius Oncology (NASDAQ:CTOR) last released its quarterly earnings results on Friday, February 13th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The firm had revenue of $3.94 million for the quarter, compared to the consensus estimate of $4.37 million.

Institutional Trading of Citius Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of CTOR. OMERS ADMINISTRATION Corp bought a new position in shares of Citius Oncology in the 4th quarter worth about $104,000. Geode Capital Management LLC grew its holdings in Citius Oncology by 31.6% in the fourth quarter. Geode Capital Management LLC now owns 220,047 shares of the company’s stock worth $220,000 after purchasing an additional 52,875 shares during the period. IFP Advisors Inc grew its holdings in Citius Oncology by 163.2% in the fourth quarter. IFP Advisors Inc now owns 87,424 shares of the company’s stock worth $87,000 after purchasing an additional 54,209 shares during the period. Armistice Capital LLC bought a new position in shares of Citius Oncology during the third quarter valued at approximately $15,582,000. Finally, Citadel Advisors LLC bought a new position in shares of Citius Oncology during the third quarter valued at approximately $36,000. 70.52% of the stock is owned by hedge funds and other institutional investors.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.